Clinical TrialMay 29, 2026, 06:52 AM
Pharvaris to Present Deucrictibant Clinical Data at EAACI 2026 Congress
AI Summary
Pharvaris announced the acceptance of eight abstracts for presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026. This includes one oral presentation and seven flash talk/poster presentations, highlighting significant progress in its clinical programs. The presentations will detail results from the Phase 3 RAPIDe-3 trial for on-demand treatment of hereditary angioedema (HAE) attacks, clinical cardiovascular safety assessments, and long-term safety and efficacy data from the Phase 2 CHAPTER-1 open-label extension study for HAE prophylaxis. The company continues to advance its oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases.
Key Highlights
- Pharvaris announced one abstract accepted for oral presentation at EAACI 2026.
- Seven abstracts accepted for flash talk/poster presentations at EAACI 2026.
- Oral presentation details end of progression results from Phase 3 RAPIDe-3 trial.
- Poster presentations include clinical cardiovascular safety of deucrictibant.
- Additional posters cover full results of Phase 3 RAPIDe-3 trial for HAE.
- Flash talks present long-term safety and efficacy from Phase 2 CHAPTER-1 OLE study.
- Further flash talks highlight improved disease control and quality of life from CHAPTER-1 OLE.
- Presentations are scheduled for June 12-15, 2026, in Istanbul, Turkey.
Price Impact
More from PHVS